Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours

European Journal of Cancer

Volumn 45, Issue 10, 2009, Pages 1764-1772

  Kitzen, J J E M ^a   de Jonge, M J A ^a   Lamers, C H J ^a   Eskens, F A L M ^a   van der Biessen, D ^a   van Doorn, L ^a   ter Steeg, J ^a   Brandely, M ^b   Puozzo, Ch ^b   Verweij, J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Pharmacodynamic; Pharmacokinetic; Targeted therapy; Triptolide

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; F 60008; TRIPTOLIDE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANAMNESIS; ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BLOOD CELL COUNT; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG HALF LIFE; ENZYME ACTIVITY; FATIGUE; FEMALE; HUMAN; LIVER TOXICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METABOLIC CLEARANCE RATE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NEUTROPENIC SEPSIS; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SEPSIS; SOLID TUMOR; VOMITING;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; NEOPLASMS; PHENANTHRENES;

EID: 67049110419     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.01.026     Document Type: Article

References (23)

1. Wang C.Y., Mayo M.W., and Baldwin A.S. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-KappaB. Science 274 (1996) 784-787
2. Wang C.Y., Cusack Jr. J.C., Liu E., et al. Control of inducible chemoresistance: enhanced anti-tumour therapy through increased apoptosis by inhibition of NF-κB. Nat Med 5 (1999) 412-417
3. Beg A.A., and Baltimore D. An essential role for NF-κB in preventing TNF-alpha-induced cell death. Science 274 (1996) 782-784
4. Van Antwerp D.J., Martin S.J., Kafri T., et al. Suppression of TNF induced apoptosis by NF-κB. Science 274 (1996) 787-789
5. Liu Z.G., Hsu H., Goeddel D.V., et al. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death. Cell 87 (1996) 565-575
6. 1 inhibits NF-κB/Rel activity inducing apoptosis of B-cells: transcriptional activation of ikBa. Immunity 5 (1996) 31-40
7. Lipsky P.E., and Xue-Lian T. A potential new treatment for rheumatoid arthritis: thunder god vine. Se. Arthritis Rheum 26 (1997) 713-723
8. Bunz F., Hwang P.M., Torrance C., et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1041 (1999) 263-269
9. Wang Y.A., Elson A., and Leder P. Loss of p21 increases sensitivity to ionizing radiation and delays the onset of lymphoma in atm-deficient mice. Proc Natl Acad Sci USA 94 (1997) 14590-14595
10. Chang W.T., Kang J.J., Lee K.Y., et al. Triptolide and chemotherapy cooperate in tumour cell apoptosis. A role for the p53 pathway. J Biol Chem 276 (2001) 2221-2227
11. Lee K.Y., Chang W.T., Qiu D., et al. PG490 (triptolide) cooperates with tumor necrosis factor-α to induce apoptosis in tumor cells. J Biol Chem 274 (1999) 13451-13455
12. YinJun L., Jie J., and YunGui W. Triptolide inhibits transcription factor NF-kappaB and induces apoptosis of multiple myeloma cells. Leukemia Res 29 (2005) 99-105
13. Lee K.Y., Park J.S., Jee Y.K., et al. Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-κB activation. Exp Mol Med 34 (2002) 462-468
14. Westerheide S.D., Kawahara T.L.A., Orton K., et al. Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death. J Biol Chem 281 (2006) 9616-9622
15. Yang S.O., Chen J.O., Guo Z., et al. Triptolide inhibits the growth and metastasis of solid tumours. Mol Cancer Ther 2 (2003) 65-72
16. Simon R., Freidlin B., Rubinstein L., et al. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89 (1997) 1138-1147
17. Therase P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 92 3 (2000) 205-216
18. Lamers C.H., Gratema J.W., Pouw N.M., et al. Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: implications for loss of transgene expression. Hum Gene Ther 16 12 (2005) 1452-1462
19. Maino V.C., Suni M.A., Ruitenberg J.J., et al. Rapid flow cytometric method for measuring lymphocyte subset activation. Cytometry 20 2 (1995) 127-133
20. Maino V.C. Rapid assessment of antigen induced cytokine expression in memory T cells by flow cytometry. Vet Immunol Immunopathol 63 1-2 (1998) 199-207
21. Nakanishi C., and Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev 5 (2005) 297-309
22. Sun S.Y., Hail Jr. N., and Lotan R. Apoptosis as a novel target for cancer chemoprevention. JNCI 6-96 9 (2004) 662-672
23. Ravi R., and Bedi A. NF-κB in cancer - a friend turned foe. Drug Resist Update 7 (2004) 53-67